T-box 2 expression is a useful indicator of the response to neoadjuvant chemotherapy for patients with locally advanced uterine cervical squamous cell carcinoma.
T-box 2
chemoresistance
neoadjuvant chemotherapy
predictive biomarker
uterine cervical squamous cell carcinoma
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
22
03
2021
accepted:
06
08
2021
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
21
9
2021
Statut:
ppublish
Résumé
Platinum-based concurrent chemoradiotherapy is the standard treatment for patients with locally advanced uterine cervical squamous cell carcinoma. Reducing the tumor size by administering neoadjuvant chemotherapy (NAC) is beneficial for successful hysterectomy, resulting in a more favorable prognosis. Therefore, identifying biomarkers that predict the effectiveness of NAC in patients with cervical squamous cell carcinoma remains a priority. Cancer cells widely express T-box 2 (TBX2), which contributes to the resistance to DNA-damaging chemotherapeutic agents. The present study aimed to determine the association between TBX2 protein expression in tumor tissues and the efficacy of NAC in locally advanced uterine cervical squamous cell carcinoma using immunohistochemistry. Data from 46 patients with locally advanced uterine cervical squamous cell carcinoma were classified into two groups based on their effective or ineffective response to NAC treatment. In addition, the effect of small interfering RNA-mediated knockdown of TBX2 on the sensitivity of cervical cancer cells to cisplatin was investigated
Identifiants
pubmed: 34539859
doi: 10.3892/ol.2021.13016
pii: OL-0-0-13016
pmc: PMC8436333
doi:
Types de publication
Journal Article
Langues
eng
Pagination
755Informations de copyright
Copyright: © Inoue et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Virchows Arch. 2005 Sep;447(3):626-33
pubmed: 15968547
Oncogene. 2008 Feb 7;27(7):976-84
pubmed: 17700536
Oncol Rep. 2000 Jan-Feb;7(1):141-4
pubmed: 10601608
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Oncotarget. 2014 Mar 15;5(5):1304-14
pubmed: 24675421
J Invest Surg. 2020 Dec 8;:1-7
pubmed: 33289585
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Pharmacol Rev. 2012 Jul;64(3):706-21
pubmed: 22659329
Cancer Lett. 2009 Jun 18;278(2):230-240
pubmed: 19216023
Oncol Lett. 2016 Dec;12(6):4305-4311
pubmed: 28105146
Br J Cancer. 2014 Jul 15;111(2):339-54
pubmed: 24921914
Oncotarget. 2014 Sep 15;5(17):7776-87
pubmed: 25277200
Int J Clin Exp Med. 2014 Dec 15;7(12):5394-402
pubmed: 25664048
Development. 2014 Oct;141(20):3819-33
pubmed: 25294936
Cancer Res. 2005 Mar 15;65(6):2260-8
pubmed: 15781639
J Clin Oncol. 1995 Feb;13(2):444-51
pubmed: 7844607
Acta Pharmacol Sin. 2011 Jul;32(7):939-46
pubmed: 21666704
Ann Surg Oncol. 2007 Sep;14(9):2643-8
pubmed: 17562114
Front Oncol. 2020 Nov 05;10:570258
pubmed: 33251136
Genes Cancer. 2010 Mar;1(3):272-82
pubmed: 21779450
Nat Genet. 2000 Nov;26(3):291-9
pubmed: 11062467
Gynecol Oncol. 2020 May;157(2):536-541
pubmed: 32173046
Cancer Res. 1995 Jan 15;55(2):237-41
pubmed: 7812951
N Engl J Med. 1999 Apr 15;340(15):1137-43
pubmed: 10202164
Neoplasma. 2014;61(4):476-80
pubmed: 25027744
Genes Chromosomes Cancer. 2002 Dec;35(4):353-8
pubmed: 12378529
Fertil Steril. 2021 Jan;115(1):148-156
pubmed: 33092819
J Clin Oncol. 1991 Jun;9(6):970-7
pubmed: 1709686
Clin Med Insights Oncol. 2010 Apr 20;4:15-34
pubmed: 20567632
Nat Rev Drug Discov. 2005 Apr;4(4):307-20
pubmed: 15789122
Exp Cell Res. 2006 Jul 15;312(12):2358-66
pubmed: 16730707
Cell Death Dis. 2013 Oct 10;4:e846
pubmed: 24113180
Int J Gynaecol Obstet. 2009 May;105(2):103-4
pubmed: 19367689
IUBMB Life. 2010 Feb;62(2):92-102
pubmed: 19960541
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1337-45
pubmed: 7635773
J Biol Chem. 2008 Jan 4;283(1):388-397
pubmed: 17959603
Clin Cancer Res. 2008 Mar 1;14(5):1291-5
pubmed: 18316546
Oncogene. 2012 Apr 12;31(15):1869-83
pubmed: 21892204
Mol Cancer Ther. 2008 Mar;7(3):698-703
pubmed: 18347154
Oncogene. 2011 Dec 1;30(48):4814-23
pubmed: 21625209
Drug Resist Updat. 2002 Jul-Aug;5(3-4):147-61
pubmed: 12237082
Cancer Res. 2017 Mar 15;77(6):1331-1344
pubmed: 28108510
Oncol Lett. 2015 Sep;10(3):1689-1693
pubmed: 26622733
Mini Rev Med Chem. 2002 Apr;2(2):103-11
pubmed: 12370072
J Clin Oncol. 2004 Mar 1;22(5):872-80
pubmed: 14990643
Mol Cancer Ther. 2013 Oct;12(10):2157-66
pubmed: 23956056